{"filings":[{"id":106606,"accession_number":"0001493152-26-007574","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Sigyn Therapeutics raises ~$61.5k via three convertible notes at 35% discount","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered three convertible note purchase agreements with Brio Capital, Osher Capital, and Lambda Venture Partners.","Total principal amount of $72,222.21 (~$61,500 net proceeds) at 8% interest per annum.","Notes convertible into common stock at a 35% discount to the lowest traded price over prior 20 trading days.","No warrants issued; issuance exempt under Section 4(a)(2) as sales to sophisticated investors.","Notes have a one-year maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139635,"accession_number":"0001641172-25-024303","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Three directors resign after D&O insurance lapse; $550K convertible note issued","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Directors Richa Nand, Michael Ryan, and Christopher Wetzel resigned on Aug 7-8, 2025 due to lapse of D&O coverage.","D&O insurance policy expired Aug 4, 2025; no replacement in place; company evaluating alternatives.","Entered agreement with Lambda Venture Partners for up to $550K principal, $500K funding; first tranche $110K/$100K.","Notes bear 8% interest, one-year term, convertible at 35% discount to lowest traded price in prior 10 days.","No warrants issued; securities sold under Section 4(a)(2) exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175570,"accession_number":"0001493152-25-009462","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sigyn Therapeutics CFO Gerald DeCiccio Retires; CEO James Joyce Appointed Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Gerald DeCiccio retired effective February 26, 2025, with no disagreement with the company.","CEO James Joyce will serve as interim CFO following DeCiccio's retirement.","Sigyn entered into a Consulting Agreement with DeCiccio for continued financial support services.","CEO released a letter on March 5, 2025, outlining Sigyn Therapy's potential against emerging viral threats.","Sigyn Therapy targets viruses, bacterial toxins, inflammatory cytokines, and has a clinical strategy for ESRD patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175569,"accession_number":"0001493152-25-002575","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sigyn Therapeutics appoints Michael Ryan to board effective Jan 11, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Ryan appointed to board; will serve until next stockholder meeting or successor elected.","Ryan is a founder director of Irrus Investments, largest angel syndicate in Ireland, with €40M+ invested in 35 life science and tech firms.","Compensation: $30,000 annual cash retainer plus $50,000 in restricted stock units or options, vesting quarterly over one year.","Previously CEO of Sedana Medical (Nasdaq First North) and Artema Medical (acquired by Datascope)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175568,"accession_number":"0001493152-25-001074","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Sigyn Therapeutics reduces authorized common shares to 100M via charter amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Amendment decreasing authorized common stock to 100 million shares (par value $0.0001).","Authorized preferred stock unchanged at 10 million shares (par value $0.0001).","Amendment effective upon filing on December 30, 2024.","No other changes to the Amended and Restated Certificate of Incorporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192518,"accession_number":"0001493152-24-041287","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Sigyn Therapeutics exchanges 246,259 warrants for 184,699 restricted shares; no warrants outstanding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 246,259 stock purchase warrants from 15 holders for 184,699 restricted common shares.","No warrants remain outstanding; all previously issued warrants extinguished.","Outstanding common shares increased to 1,605,377 from 1,420,678.","Transaction exempt under Section 4(a)(2); no brokerage fees paid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192516,"accession_number":"0001493152-24-041285","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K/A","filed_at":"2024-10-16T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Sigyn corrects prior error; debenture conversion adds 118,700 shares, 9.1% share increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrected prior error: sellers were not controlled by an executive officer.","$474,793 of convertible debentures converted at $4.00/share for 118,700 shares.","Shares issued with Rule 144 legend, exempt under Section 4(a)(2).","Outstanding common shares increased from 1,301,978 to 1,420,678."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192517,"accession_number":"0001493152-24-039594","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Sigyn Therapeutics issues 118,700 shares on conversion of $474,793 in debentures at $4.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders of $474,793 in convertible debentures converted at $4.00/share; 118,700 restricted shares issued.","Outstanding common shares increased from 1,301,978 to 1,420,678 as a result.","Conversion exempt from registration under Section 4(a)(2); holders are executive-officer-controlled accredited investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226818,"accession_number":"0001493152-24-022945","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sigyn Therapeutics reports conversion of $226,903 in debentures at $6.00 per share, issuing 37,820 shares.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders converted $226,903 of Original Issue Discount Senior Convertible Debentures at avg. exercise price of $6.00/share.","Company issued 37,820 shares of common stock to debenture holders.","Outstanding common shares increased from 1,225,833 to 1,263,653 as a result.","Conversions occurred from May 30 to June 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226817,"accession_number":"0001493152-24-020007","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sigyn Therapeutics files PCT patent for ImmunePrep platform to enhance antibody delivery for cancer treatment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed PCT application US24/28579 on May 9, 2024 for 'DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES'.","Patent covers ImmunePrep platform aimed at improving delivery of immunotherapeutic antibodies for cancer.","Inventors listed: Chairman and CEO James A. Joyce and Annette M. Marleau."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226816,"accession_number":"0001493152-24-014866","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Sigyn Therapeutics converts $841k debentures to Series B Preferred; extends other debt to 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Brio Capital converts $220,420 debentures into 292.4 shares of Series B Convertible Preferred Stock.","Osher Capital converts $621,000 debentures into 823.86 shares of Series B Convertible Preferred Stock.","Each Series B share is convertible into 125.63 common shares, subject to anti-dilution adjustments.","Brio and Osher amend additional debentures: maturity extended to March 31, 2025; principal increased to $125k and $316,350 respectively.","Additional automatic conversion of $1,856,566 aggregate debentures into Series B Preferred upon NASDAQ listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}